In the EU, the Phase 3b trial will evaluate eGOS after six months as the primary efficacy endpoint as in the Phase 3a trial. Based on the post hoc analysis of the initial Phase 2a and 3a trials, the drug infusion will start between four and 12 hours after injury, as opposed to six...
The pheromone content of the female moth showed the periodic change; the pheromone increased in photophase period and decreased in the scotophase. The pheromone content of the female moth reached the maximal level between 33 and 36 hours after eclosion. Subsequently, the pheromone content of the...
There is not only a significant relationship between the ALM index and HGS, but also some direct relationship between GNRI and HGS. In females, there was no significant association between the GNRI or ALM index and HGS. These suggest that, for both sexes, nutritional supplementation and exercise...
arrow keys and were instructed to respond as soon as possible once they had made the decision (DECISION phase). The chosen stimulus was immediately highlighted by a gray frame (CONFIRMATION phase). Later, the rewarded stimulus was revealed in the center (FEEDBACK phase). ITI, inter-trial ...
aAlthough most trials use equal randomisation (such as 1:1 for two groups), it is helpful to provide the allocation ratio explicitly. For drug trials, specifying the phase of the trial (I-IV) may also be relevant. 虽然多数试验使用相等的随机化(例如1:1为二个小组),明确地提供分派比率是有用...
It is noteworthy that the strength of surrogacy of these intermediate endpoints in targeted therapy is greater than that in immunotherapy.According to the arm-level and trial level-analysis, we suggest that in phase II and III trials of targeted therapy and immunotherapy for NSCLC patients: 1) ...
It has been argued that a target difference should always be both important and realistic [29], which would seem particularly apt when designing a definitive (Phase III) superiority RCT. In a sample size calculation for a RCT, the target difference between the treatment groups, strictly relates...
Cellid CEO Kang Chang-yul explains the results of phase 1 and phase 2a trials of AdCLD-CoV19, a Covid-19 vaccine candidate, at a virtual symposium on Tuesday. The company also said it planned to conduct a separate study early next year to fight the Delta variant. ...
The main difference between Arexvy and Abrysvo is in their composition. Arexvy is an adjuvanted vaccine which means it contains a substance that helps to enhance the effects of the vaccine by boosting the response of the immune system. Abrysvo contains no adjuvant, but it is bivalent, meani...
They received sham tACS and anti-phase tACS (180° phase difference between P3 and P4) on two different days just like Experiment 1. Figure 1 Stimulation sites and trial procedure for Experiment 1: Electrodes were placed over P3 and P4 with no phase offset, and the reference electrode was ...